ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Eplontersen (Wainzua)

Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.

CHMP opinion 17 Oct 2024 → EU licence 6 Mar 2025 · AstraZeneca AB

Research

Neurology · Eur J Neurol · 2026-04-01

Exploratory analysis of a phase 3 trial in 144 patients with ATTRv amyloidosis with polyneuropathy: eplontersen reduced serum TTR by 70.6% to 85.0% vs historical placebo across genetic variant groups, with neuropathy scores generally maintained and quality of life improved.

Secondary analysisn = 144 patients
Gillmore et al. Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.